Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily summary: Geopolitics and debt continue to weigh on valuations
US OPEN: Market Cornered After Jackson Hole
PG&E shares plunge 18% 🚩 Panic hits U.S. utility stocks exposed to wildfire liabilities
Bakkafrost shares fall 6% after Q2 results 📉 Does the seafood processing giant have a problem?